CVS or Amniocentesis After NIPT: Risk and Diagnostic-Yield Calculator

Compare procedure-related loss with the chance diagnostic testing finds trisomy 21, 18 or 13 after NIPT.

CVS or amniocentesis collects the sample, but microarray is a separate laboratory test and is not always included.

A high-risk NIPT is a screening result, not a diagnosis. The microarray estimate is shown only for a low-risk standard NIPT and assumes no structural abnormality has been found on ultrasound.
Change the procedure-loss estimate
1 in

The input starts with the ACOG US patient-information default for the selected procedure. Replace it with your clinic’s estimate if you have one.

Change NIPT or starting-chance details
1 in

Age-based default

1 in

Age-based default

1 in

Age-based default

The defaults are population estimates for a standard NIPT. Use a report or clinician-provided value if it better reflects your test or pregnancy.

Sources and how they were used

  • ACOG amniocentesis guidance: The default procedure-related loss estimates are ACOG's US patient-information figures: about 1 in 455 for CVS and 1 in 900 for amniocentesis. They are broad defaults, not an individual clinic prediction.
  • SMFM Consult Series #74: Supplies the default sensitivity values for a standard NIPT for trisomy 21, 18 and 13.
  • Genetic Support Foundation NIPT Predictive Value Calculator: Supplies the age-based starting chances at about 16 weeks and the predictive-value approach used for low-risk and high-risk NIPT results.
  • Maya et al. 2022: Supplies the age-group defaults for clinically significant copy-number findings remaining after theoretically excluding standard T21/T18/T13 NIPT-detectable findings. The study used an amniocentesis microarray cohort without structural ultrasound anomalies; this limitation is shown with the result.
  • ACOG microarray guidance: Explains that microarray can detect submicroscopic copy-number changes beyond a standard karyotype and that diagnostic scope depends on the laboratory test ordered.
  • Salomon et al. 2019: A meta-analysis used to explain why procedure-related loss estimates vary by study and can be lower when comparison pregnancies have similar baseline risks.

Method reviewed: 12 July 2026. This is educational context, not a recommendation for or against testing.